By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Abbott said today it will provide a companion diagnostic for an investigational cancer therapy being developed by Merck.

Under the terms of the deal, Abbott will use its fluorescence in situ hybridization technology to develop a test to identify deletions of the TP53 gene in cancer patients. The assay will be evaluated in clinical trials for its ability to select the most appropriate patients for Merck's therapy.

Other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: oral microbiomes of dogs and their owners, Plasmodium vivax population structure, and more.

The American Society of Human Genetics has issued a position statement on genetic testing of children.

The White House seeks to update how biotechnology products are regulated.

Team science leads some researchers to get lost in the shuffle, the Chronicle of Higher Education reports.